# Venetoclax + obinutuzumab (12 months)

Source: https://onco.cc/pairings/venetoclax-plus-obinutuzumab/  
OnCo record `venetoclax-plus-obinutuzumab` (Pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Venetoclax plus obinutuzumab, one year of a pill plus an antibody, was the first fixed-duration, chemotherapy-free CLL regimen, with half of patients still in remission at six years.

## Summary

This combination gives one year of venetoclax, a BCL-2 inhibitor, with the CD20 antibody obinutuzumab in chronic lymphocytic leukaemia; it was the first fixed-duration, chemotherapy-free regimen for the disease. Obinutuzumab debulks the leukaemia and reduces the risk of tumour lysis syndrome before venetoclax is ramped up, and adds antibody-dependent cellular cytotoxicity, while venetoclax clears measurable residual disease. The evidence is two positive phase 3 trials: CLL14 in unfit patients, where a large share remain in remission at long follow-up, and CLL13 (GAIA) in fit patients, where obinutuzumab outperformed rituximab as the venetoclax partner and adding ibrutinib deepened the effect further. The regimen is described in the CLL14 paper.

## Fields

- Kind: Pairing
- Last checked: 2026-09-07
- Pairs: Venetoclax + Obinutuzumab
- Type: combination
- Rationale: Obinutuzumab debulks and reduces TLS risk before venetoclax ramp-up and adds ADCC-mediated killing; venetoclax clears MRD.
- Evidence: Two positive phase 3 trials.

## Sources

- ClinicalTrials.gov NCT02242942: CLL14: https://clinicaltrials.gov/study/NCT02242942
- ClinicalTrials.gov NCT02950051: CLL13 / GAIA: https://clinicaltrials.gov/study/NCT02950051

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Chronic lymphocytic leukaemia, first treatment](https://onco.cc/cancers/cll-treatment-naive/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [CD20](https://onco.cc/targets/cd20/)
- drugs: [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- trials: [CLL13 / GAIA](https://onco.cc/trials/cll13-gaia/), [CLL14](https://onco.cc/trials/cll14/)
- key papers: [CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients](https://onco.cc/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/)

---
JSON: https://onco.cc/api/v1/entities/venetoclax-plus-obinutuzumab.json